Evaluation of adipocytokines in children with chronic kidney disease

Endokrynologia Polska

Volumn 66, Issue 2, 2015, Pages 100-107

  Szczepańska, Maria ^a   Machura, Edyta ^a   Adamczyk, Piotr ^a   Swiętochowska, Elzbieta ^a   Trembecka Dubel, Elzbieta ^a   Lipiec, Katarzyna ^a   Jędzura, Agnieszka ^a   Ziora, Katarzyna ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Adipocytokines; Adiponectin; Apelin; Chemerin; Children; Chronic kidney disease; Omentin; Resistin; Vaspin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANTIHYPERTENSIVE AGENT; APELIN; CHEMERIN; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; FOLIC ACID; HEMOGLOBIN; OMENTIN; RESISTIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASPIN; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; BODY SURFACE; CHILD; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DIURETIC THERAPY; END STAGE RENAL DISEASE; EVALUATION STUDY; FEMALE; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY DYSFUNCTION; LONGITUDINAL STUDY; MALE; PERITONEAL DIALYSIS; PROTEIN BLOOD LEVEL; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; YOUNG ADULT; ADIPOSE TISSUE; BLOOD; CHRONIC KIDNEY FAILURE; SECRETION (PROCESS);

ADIPOKINES; ADIPOSE TISSUE; ADOLESCENT; BIOMARKERS; CHILD; FEMALE; HUMANS; MALE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84929396080     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: 10.5603/EP.2015.0015     Document Type: Article

References (36)

1. Nehus E, Furth S, Warady B et al. Correlates of Resistin in Children with Chronic Kidney Disease: The Chronic Kidney Disease in Children Cohort. J Pediatr 2012; 161: 276-280.
2. Kamariski M, Biscardi M, Cestino L et al. Adiponectin in Children on Peritoneal Dialysis: Relationship to Insulin Resistance and Nutritional Status. Nephron Clin Pract 2009; 113: c24-c32.
3. Elshamaa MF, Sabry SM, El-Sonbaty MM et al. Adiponectin: an adipocyte-derived hormone, and its gene encoding in children with chronic kidney disease. BMC Res Notes 2012; 5: 174.
4. Maggio MC, Montaperto D, Maringhini S et al. Adiponectin, resistin and leptin in paediatric chronic renal failure: correlation with auxological and endocrine profiles. J Nephrol 2014; 27: 275-279.
5. Zhu W, Cheng KK, Vanhoutte PM et al. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 2008; 114: 361-374.
6. Mills KT, Hamm LL, Alper AB et al. Circulating Adipocytokines and Chronic Kidney Disease. PLoS ONE 2013; 8: e76902.
7. Nakamaki S, Satoh H, Kudoh A et al. Adiponectin reduces proteinuria in streptozotocin-induced diabetic Wistar rats. Experimental Biology and Medicine 2011; 236: 614-620.
8. Ladeiras-Lopes R, Ferreira-Martins J, Leite-Moreira AF. The apelinergic system: the role played in human physiology and pathology and potential therapeutic applications. Arq Bras Cardiol 2008; 90: 343-349.
9. Leal VO, Lobo JC, Stockler-Pinto MB et al. Apelin: a peptide involved in cardiovascular risk in hemodialysis patients? Ren Fail 2012; 34: 577-581.
10. El-Shehaby AM, El-Khatib MM, Battah AA et al. Apelin: a potential link between inflammation and cardiovascular disease in end stage renal disease patients. Scand J Clin Lab Invest 2010; 70: 421-427.
11. Zhang BH, Wang W, Wang H et al. Promoting Effects of the adipokine, apelin, on Diabetic Nephropathy. PLoS ONE 2013; 8: e60457.
12. Silva AP, Fragoso A, Silva C et al. What Is the Role of Apelin regarding Cardiovascular Risk and Progression of Renal Disease in Type 2 Diabetic Patients with Diabetic Nephropathy? BioMed Res Int 2013; 2013: 247649.
13. Rourke JL, Dranse HJ, Sinal CJ. Towards an integrative approach to understanding the role of chemerin in human health and disease. Obes Rev 2013; 14: 245-262.
14. Hu W, Yu Q, Zhang J et al. Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats. Inflammation 2012; 35: 1287-1293.
15. Pfau D, Bachmann A, Lössner U et al. Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care 2010; 33: 171-173.
16. de Souza Batista CM, Yang RZ, Lee MJ et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655-1661.
17. Chen HY, Lin CC, Chiu YL et al. Serum Fetuin A and Chemerin Levels Correlate with Hepatic Steatosis and Regional Adiposity in Maintenance Hemodialysis Patients. PLoS ONE 2012; 7: e38415.
18. Prats-Puig A, Bassols J, Bargalló E et al. Toward an Early Marker of Metabolic Dysfunction: Omentin-1 in Prepubertal Children. Obesity 2011; 19: 1905-1907.
19. Hida K, Wada J, Eguchi J et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005; 102: 10610-10615.
20. Seeger J, Ziegelmeier M, Bachmann A et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008; 93: 247-251.
21. Phalitakul S, Okada M, Hara Y et al. Vaspin prevents methylglyoxal-induced apoptosis in human vascular endothelial cells by inhibiting reactive oxygen species generation. Acta Physiol (Oxf) 2013; 209: 212-219.
22. Karbowska A, Boratyńska M, Klinger M. Rezystyna-czynnik patogenetyczny czy biomarker zaburzeń metabolicznych i zapalenia? Postepy Hig Med Dosw 2009; 63: 485-491.
23. Stępień M, Stępień A, Wlazeł RN et al. Obesity indices and adipokines in non-diabetic obese patients. Med Sci Monit 2013; 19: 1063-1072.
24. Miyamoto S, Sharma K. Adipokines protecting CKD. Nephrol Dial Transplant 2013; 28: iv15-iv22.
25. Rüster Ch, Wolf G. Adipokines promote chronic kidney disease. Nephrol Dial Transplant 2013; 28: iv8-iv14.
26. Alam A, Molnar MZ, Czira ME et al. Serum Adiponectin Levels and Mortality after Kidney Transplantation. CJASN 2013; 8: 460-467.
27. Niemczyk S, Romejko-Ciepielewska K, Niemczyk L. Adipocytokines and sex hormone disorders in patients with chronic renal failure (CRF). Endokrynol Pol 2012; 63: 148-155.
28. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556.
29. Kaynar K, Kural BV, Ulusoy S et al. Is there any interaction of resistin and adiponectin levels with protein-energy wasting among patients with chronic kidney disease. Hemodial Int 2014; 18: 153-162.
30. Mafra D, Lobo JC, Farage NE et al. The relationship between apelin and parathyroid hormone in hemodialysis patients. Ren Fail 2012; 34: 970-973.
31. Malyszko J, Malyszko JS, Pawlak K et al. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure.
32. Adv Med Sci 2008; 53: 32-36.
33. Yamamoto T, Qureshi AR, Anderstam B et al. Clinical importance of an elevated circulating chemerin level in incident dialysis patients. Nephrol Dial Transplant 2010; 25: 4017-4023.
34. Shang FJ, Wang JP, Liu XT et al. Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers 2011; 16: 657-662.
35. Moreno-Navarrete JM, Ortega F, Castro A et al. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring) 2011; 19: 1552-1559.
36. Alcelik A, Tosun M, Ozlu MF et al. Serum levels of omentin in end-stage renal disease patients. Kidney Blood Press Res 2012; 35: 511-516.